Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas

Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas

Doxorubicin is a widely used anticancer agent as a first-line treatment for various tumor types, including sarcomas. Its use is hampered by adverse events, among which is the risk of dose dependence. The potential cardiotoxicity, which increases with higher doses, poses a significant challenge to it...

Full description

Bibliographic Details
Main Authors: Angela Buonadonna, Simona Scalone, Davide Lombardi, Arianna Fumagalli, Alessandra Guglielmi, Chiara Lestuzzi, Jerry Polesel, Vincenzo Canzonieri, Stefano Lamon, Petros Giovanis, Sara Gagno, Giuseppe Corona, Maurizio Mascarin, Claudio Belluco, Antonino De Paoli, Gianpiero Fasola, Fabio Puglisi, Gianmaria Miolo
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Cancers
Subjects:
soft tissue sarcoma
non-pegylated doxorubicin
doxorubicin
ifosfamide
Online Access:https://www.mdpi.com/2072-6694/15/20/5036

Internet

https://www.mdpi.com/2072-6694/15/20/5036

Similar Items